Cargando…
Recurrence or reactivation of SARS-CoV-2 infection after immunosuppressive therapy in patients with ANCA-associated vasculitis and COVID-19
Abstract. Acute tubular injury is the lesion most frequently described in this disease. However, four cases of ANCA-associated vasculitis (AAV) with COVID-19 with pauci-immune glomerulonephritis have recently been described. We report the case of an African woman, aged 70, in whom we diagnosed an AA...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dustri-Verlag Dr. Karl Feistle
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750963/ https://www.ncbi.nlm.nih.gov/pubmed/35028280 http://dx.doi.org/10.5414/CNCS110567 |
_version_ | 1784631580238544896 |
---|---|
author | Mbengue, Mansour Bigirimana, Bede Irankunda, Lolly Romeo Dial, Mohamed Cherif Niang, Abdou |
author_facet | Mbengue, Mansour Bigirimana, Bede Irankunda, Lolly Romeo Dial, Mohamed Cherif Niang, Abdou |
author_sort | Mbengue, Mansour |
collection | PubMed |
description | Abstract. Acute tubular injury is the lesion most frequently described in this disease. However, four cases of ANCA-associated vasculitis (AAV) with COVID-19 with pauci-immune glomerulonephritis have recently been described. We report the case of an African woman, aged 70, in whom we diagnosed an AAV with pauci-immune glomerulonephritis in the context of COVID-19. She was treated with hydroxychloroquine and azithromycin for COVID-19. Corticosteroids and cyclophosphamide have been used for the treatment of vasculitis. The evolution was marked by the reappearance of COVID-19 one month after the beginning of an immunosuppressive therapy. The patient died a week later from respiratory failure. The occurrence of AAV during COVID-19 may not be due an unfortunate association but triggered by infection with SARS-CoV-2. The use of immunosuppressive therapy should be discussed due to the potential risk of reactivation or recurrence of the viral infection. |
format | Online Article Text |
id | pubmed-8750963 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dustri-Verlag Dr. Karl Feistle |
record_format | MEDLINE/PubMed |
spelling | pubmed-87509632022-01-12 Recurrence or reactivation of SARS-CoV-2 infection after immunosuppressive therapy in patients with ANCA-associated vasculitis and COVID-19 Mbengue, Mansour Bigirimana, Bede Irankunda, Lolly Romeo Dial, Mohamed Cherif Niang, Abdou Clin Nephrol Case Stud Case Report Abstract. Acute tubular injury is the lesion most frequently described in this disease. However, four cases of ANCA-associated vasculitis (AAV) with COVID-19 with pauci-immune glomerulonephritis have recently been described. We report the case of an African woman, aged 70, in whom we diagnosed an AAV with pauci-immune glomerulonephritis in the context of COVID-19. She was treated with hydroxychloroquine and azithromycin for COVID-19. Corticosteroids and cyclophosphamide have been used for the treatment of vasculitis. The evolution was marked by the reappearance of COVID-19 one month after the beginning of an immunosuppressive therapy. The patient died a week later from respiratory failure. The occurrence of AAV during COVID-19 may not be due an unfortunate association but triggered by infection with SARS-CoV-2. The use of immunosuppressive therapy should be discussed due to the potential risk of reactivation or recurrence of the viral infection. Dustri-Verlag Dr. Karl Feistle 2022-01-05 /pmc/articles/PMC8750963/ /pubmed/35028280 http://dx.doi.org/10.5414/CNCS110567 Text en © Dustri-Verlag Dr. K. Feistle https://creativecommons.org/licenses/by/2.5/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Mbengue, Mansour Bigirimana, Bede Irankunda, Lolly Romeo Dial, Mohamed Cherif Niang, Abdou Recurrence or reactivation of SARS-CoV-2 infection after immunosuppressive therapy in patients with ANCA-associated vasculitis and COVID-19 |
title | Recurrence or reactivation of SARS-CoV-2 infection after immunosuppressive therapy in patients with ANCA-associated vasculitis and COVID-19 |
title_full | Recurrence or reactivation of SARS-CoV-2 infection after immunosuppressive therapy in patients with ANCA-associated vasculitis and COVID-19 |
title_fullStr | Recurrence or reactivation of SARS-CoV-2 infection after immunosuppressive therapy in patients with ANCA-associated vasculitis and COVID-19 |
title_full_unstemmed | Recurrence or reactivation of SARS-CoV-2 infection after immunosuppressive therapy in patients with ANCA-associated vasculitis and COVID-19 |
title_short | Recurrence or reactivation of SARS-CoV-2 infection after immunosuppressive therapy in patients with ANCA-associated vasculitis and COVID-19 |
title_sort | recurrence or reactivation of sars-cov-2 infection after immunosuppressive therapy in patients with anca-associated vasculitis and covid-19 |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750963/ https://www.ncbi.nlm.nih.gov/pubmed/35028280 http://dx.doi.org/10.5414/CNCS110567 |
work_keys_str_mv | AT mbenguemansour recurrenceorreactivationofsarscov2infectionafterimmunosuppressivetherapyinpatientswithancaassociatedvasculitisandcovid19 AT bigirimanabede recurrenceorreactivationofsarscov2infectionafterimmunosuppressivetherapyinpatientswithancaassociatedvasculitisandcovid19 AT irankundalollyromeo recurrenceorreactivationofsarscov2infectionafterimmunosuppressivetherapyinpatientswithancaassociatedvasculitisandcovid19 AT dialmohamedcherif recurrenceorreactivationofsarscov2infectionafterimmunosuppressivetherapyinpatientswithancaassociatedvasculitisandcovid19 AT niangabdou recurrenceorreactivationofsarscov2infectionafterimmunosuppressivetherapyinpatientswithancaassociatedvasculitisandcovid19 |